How should we use anti-CTLA-4 antibodies?

Aurélien Marabelle, Alexander Eggermont

Research output: Contribution to journal › Comment/debate

7 Citations (Scopus)

Original language	English
Pages (from-to)	2686-2688
Number of pages	3
Journal	European Journal of Cancer
Volume	51
Issue number	17
DOIs	https://doi.org/10.1016/j.ejca.2015.09.002
Publication status	Published - 1 Nov 2015
Externally published	Yes

Access to Document

10.1016/j.ejca.2015.09.002

Cite this

@article{583b8646ed024117af68cac2b401a3c3,

title = "How should we use anti-CTLA-4 antibodies?",

author = "Aur{\'e}lien Marabelle and Alexander Eggermont",

year = "2015",

month = nov,

day = "1",

doi = "10.1016/j.ejca.2015.09.002",

language = "English",

volume = "51",

pages = "2686--2688",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

number = "17",

}

TY - JOUR

T1 - How should we use anti-CTLA-4 antibodies?

AU - Marabelle, Aurélien

AU - Eggermont, Alexander

PY - 2015/11/1

Y1 - 2015/11/1

UR - http://www.scopus.com/inward/record.url?scp=84963604448&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2015.09.002

DO - 10.1016/j.ejca.2015.09.002

M3 - Comment/debate

C2 - 26613660

AN - SCOPUS:84963604448

SN - 0959-8049

VL - 51

SP - 2686

EP - 2688

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 17

ER -